Premium
The critical role of alpha‐folate receptor in the resistance of melanoma to methotrexate
Author(s) -
SánchezdelCampo Luís,
Montenegro María F.,
CabezasHerrera Juan,
RodríguezLópez José Neptuno
Publication year - 2009
Publication title -
pigment cell and melanoma research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.618
H-Index - 105
eISSN - 1755-148X
pISSN - 1755-1471
DOI - 10.1111/j.1755-148x.2009.00586.x
Subject(s) - melanoma , methotrexate , folate receptor , endocytic cycle , cancer research , receptor , pharmacology , chemistry , endocytosis , biology , cancer cell , cancer , medicine , biochemistry , immunology
Summary Although methotrexate (MTX) is an effective drug for several types of cancer, it is not active against melanoma. Experiments following methotrexate treatment indicated a reduced accumulation of the drug in the cytosolic compartment in melanoma cells, suggesting that the mechanisms that control the transport and retention of this drug could be altered in melanoma. For this reason, we analyzed the presence and function of folate receptor‐α (FRα) in melanoma cells. In this study, we have identified the presence of FRα in normal and pathological melanocytes and demonstrated that MTX is preferentially transported through this receptor in melanoma cells. FRα‐induced endocytic transport of MTX, together with drug melanosomal sequestration and cellular exportation, ensures reduced accumulation of this cytotoxic compound in intracellular compartments. The critical role of FRα in this mechanism of resistance and the therapeutic consequences of these findings are also discussed.